Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction:a Danish nationwide population-based cohort study by Green, Anders et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Initiation and persistence with dual antiplatelet therapy after acute myocardial
infarction
a Danish nationwide population-based cohort study
Green, Anders; Pottegård, Anton; Broe, Anne; Diness, Thomas Goldin; Emneus, Martha;
Hasvold, Pål; Gislason, Gunnar H
Published in:
B M J Open
DOI:
10.1136/bmjopen-2015-010880
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Green, A., Pottegård, A., Broe, A., Diness, T. G., Emneus, M., Hasvold, P., & Gislason, G. H. (2016). Initiation
and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-
based cohort study. B M J Open, 6(5), 1-11. [e010880]. https://doi.org/10.1136/bmjopen-2015-010880
Download date: 09. okt.. 2020
Initiation and persistence with dual
antiplatelet therapy after acute
myocardial infarction: a Danish
nationwide population-based cohort
study
Anders Green,1,2 Anton Pottegård,3 Anne Broe,3 Thomas Goldin Diness,4
Martha Emneus,2 Pål Hasvold,4 Gunnar H Gislason5
To cite: Green A,
Pottegård A, Broe A, et al.
Initiation and persistence with
dual antiplatelet therapy after
acute myocardial infarction: a
Danish nationwide
population-based cohort
study. BMJ Open 2016;6:
e010880. doi:10.1136/
bmjopen-2015-010880
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2015-
010880).
Received 28 December 2015
Revised 9 April 2016
Accepted 20 April 2016
For numbered affiliations see
end of article.
Correspondence to
Professor Anders Green;
anders.green@dadlnet.dk
ABSTRACT
Objectives: The study investigated dual antiplatelet
therapy (DAPT) patterns over time and patient
characteristics associated with the various
treatments in a myocardial infarction (MI)
population.
Design: A registry-based observational cohort study
was performed using antecedent data.
Setting: This study linked morbidity, mortality and
medication data from Danish national registries.
Participants: All 28 449 patients admitted to a Danish
hospital with a first-time MI and alive at discharge
from 2009 through 2012 were included.
Primary and secondary outcome measures:
Primary outcome was initiation of DAPT and secondary
outcomes comprised persistence in DAPT treatment
and switches between DAPT treatments.
Results: The overall proportion of patients prescribed
DAPT increased from 68% (CL 95% 67–69%) to 73%
(CL 95% 72–74%) from 2009 to 2012. For treatment
of patients with and without percutaneous coronary
intervention (PCI), the corresponding numbers were
from 87% (CL 95% 86–88%) to 91% (CL 95%
90–92%) and from 49% (CL 95% 47–50%) to 52%
(CL 95% 51–54%), respectively. Non-PCI patients had
a higher cardiovascular risk compared with PCI
patients. Among PCI patients, age>75 years, atrial
fibrillation, diabetes and peripheral arterial disease were
associated with a higher risk of treatment breaks for
DAPT. Among patients without PCI, ticagrelor
treatment was associated with an increased risk of
treatment breaks during the first 12 months compared
with clopidogrel treatment.
Conclusions: From 2009 to 2012, there was an
increase in the proportion of patients with MI receiving
DAPT, and a longer duration of DAPT. Still, a large
proportion of patients without PCI are discharged
either without DAPT or with a short DAPT duration.
These findings may indicate the need for more careful
attention to DAPT for patients with MI not undergoing
PCI in Denmark.
INTRODUCTION
Platelet activation and subsequent aggrega-
tion represent the key targets in the manage-
ment of acute coronary syndromes (ACS) to
prevent recurrent events. However, the inci-
dence of ACS has declined over time, sup-
porting the notion that contemporary
treatment effectively improves outcomes after
a myocardial infarction (MI).1–4 European
guidelines recommend initiation of dual
antiplatelet therapy (DAPT) with low-dose
acetyl salicylic acid (ASA) and a P2Y12 antag-
onist to reduce the risk of acute ischaemic
complications and recurrent atherothrombo-
tic events.5 This treatment is recommended
Strengths and limitations of this study
▪ Our study describes dual antiplatelet treatment in
Danish patients after myocardial infarction
during 2009–2012, making use of the nation-
wide and complete health registers that may be
linked at individual level by means of the unique
personal identification system covering all
Danish citizens.
▪ The registry data available for our study are col-
lected for administrative purposes, thereby redu-
cing potential sources of bias otherwise
introduced by selection of particular hospitals or
healthcare insurance systems.
▪ Even though coding errors cannot be ruled out
in the registry data, previous studies have
demonstrated high levels of sensitivity and speci-
ficity for cardiovascular outcomes in the Danish
health registers.
▪ Our study is limited by not including information
on unstable angina, ST segment elevation myo-
cardial infarction (STEMI), non-STEMI, blood
pressure, smoking habits, lipid profiles and
socioeconomic status.
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for up to 12 months in patients with ACS, irrespective of
whether the patient undergoes revascularisation with
percutaneous coronary intervention (PCI) or not.5 6
Previously, a nationwide Danish study described initi-
ation and persistence patterns for DAPT with clopido-
grel and ASA after MI in the years 2000–2005.7 The
study showed a high persistence with clopidogrel treat-
ment among PCI-treated patients as compared with
non-PCI patients, and a lower degree of clopidogrel use
among women and patients admitted to local hospitals.7
New P2Y12 antagonists have recently been introduced
in the treatment of patients with ACS; prasugrel received
European Medicines Agency (EMA) approval in 2009
and ticagrelor in 2011. Ticagrelor, co-administered with
ASA, is indicated for patients with ACS, including
patients managed medically, and those who are
managed with PCI or coronary artery bypass grafting
(CABG).8 Prasugrel, co-administered with ASA, is indi-
cated for patients with ACS undergoing PCI.9
In 2011, ticagrelor was recommended as first-line treat-
ment in the national Danish ACS guidelines across sub-
diagnoses.10 How these new multiple DAPT options are
used in contemporary clinical practice in Denmark and
how guideline recommendations are implemented are
not known. Also, since the indication for the different
P2Y12 antagonists differs, it is likely that the populations
treated with the respective P2Y12 antagonists diverge
with respect to their baseline characteristics. To the best
of our knowledge, this has not been investigated in a
large-scale study. Furthermore, it is of clinical relevance
to describe treatment persistence and patient character-
istics that are associated with reduced persistence.
The aim of this study was to describe the DAPT
pattern in Danish patients with MI during 2009–2012,
with the focus on comparing treatment in 2009 and
2012, that is, before and after the introduction of prasu-
grel and ticagrelor, by combining data from nationwide
registries on hospital admissions, prescription drug use
and date of mortality.
METHODS
Data sources
Data were obtained from Danish nationwide compulsory
registries on hospital admissions and prescribed drugs.
Since virtually all medical care in Denmark is provided
by the national health authorities, these data sources
allow true population-based studies with national cover-
age and high levels of completeness.11
The Danish National Prescription Registry12 contains
data on all prescribed drugs dispensed from Danish com-
munity pharmacies since 1995. Prescription data include
type of drug, date of dispensing and quantity and are
categorised according to the Anatomic Therapeutic
Chemical (ATC) index.13 Drug expenses are partially
reimbursed by the Danish healthcare authorities.
The Danish National Patient Registry contains data on
all somatic hospitalisations in Denmark since 1977 and
on outpatient visits since 1995.14 Hospital discharge and
outpatient contact diagnoses are coded according to the
International Classification of Diseases (ICD-10) from
1994 onwards.
All data sources were linked by means of the personal
identification number, a unique identifier encoding
gender and date of birth, assigned by the Danish Civil
Registration System to all Danish residents since 1968.15
The Civil Registration System contains continuously
updated data on address, date of death and migration to
and from Denmark. All record linkages were performed
by Statistics Denmark.
Study design and study population
Patients who experienced a first time ever hospital
admission related to acute MI within the observation
period 1 January 2009 to 31 December 2012 were eli-
gible for inclusion. An MI event was defined as having
an admission with a primary or secondary diagnosis
ICD-10 code of I21. Patients with a diagnosis of unstable
angina pectoris (ICD-10 code I20.0) were not included.
Further, subclassification into ST segment elevation MI
(STEMI) and non-STEMI (NSTEMI) was not performed
since ICD-10 coding specification at this level has not
been validated.
An MI episode may present as a sequence of admis-
sions to more than one hospital department and was
defined as one admission if the interval was not more
than 1 day between discharge from one hospital and
admission date at the next hospital. Only the first
episode for each individual within the observation
period was included. We also required that individuals
were discharged alive. Patients had to be Danish resi-
dents with a Danish permanent address at the time of
admission.
The study was approved by the Danish Data Protection
Agency. According to Danish law, ethical approval is not
required for registry-based studies.16
ANALYSIS
All individuals were classified according to whether they
had been dispensed DAPT or not. The use of DAPT was
analysed among individuals experiencing MI in 2009
and 2012, respectively. All analyses were stratified by type
of DAPT, study year and whether or not the patient
underwent PCI in relation to the index event.
Baseline characteristics of participants initiating DAPT
following MI
Individuals were described regarding age and gender,
the type of hospital at index event, procedures during
index event, previous diagnoses and dispensed drugs at
the time of admission.
1. Classification according to admission by type of hos-
pital according to degree of cardiological expertise
available was: local hospital, hospital without catheter-
isation laboratory (level 1); main regional hospital,
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hospital with catheterisation laboratory (level 2); ter-
tiary cardiac hospital, university hospital with cath-
eterisation laboratory (level 3).
2. Procedures during index event included angiography
(UXAC85), PCI (procedure code FNG) and CABG
(procedure code FNA-FNE). We included CABG per-
formed up to 30 days after discharge. Throughout
the study period, procedures were coded according
to the Nordic classification scheme.17
3. Previous diagnoses (other than those related to MI)
registered in the Patient Registry up to 5 years prior
to the admission for index MI were included. For a
full list of diagnoses and definitions, see online sup-
plementary appendix A.
4. Drug use was defined as having filled a prescription
for the given drug according to the Prescription
Registry within 180 days prior to the index admission
and up to 30 days following discharge. For a full list
of drugs included, see online supplementary appen-
dix B.
Persistence to DAPT following treatment initiation
DAPTs were defined as the concomitant use of low-dose
ASA and a P2Y12 antagonist, and were further subcate-
gorised by the specific P2Y12 antagonists. The main
drugs examined were the three P2Y12 antagonists cur-
rently available in Denmark, that is, clopidogrel (ATC
B01AC04), prasugrel (B01AC22) and ticagrelor
(B01AC24), as well as low-dose ASA (B01AC06 or
N02BA01). For all four drugs, use was defined as having
filled a prescription for the given drug within 90 days
prior to the admission to 30 days after the admission.
Individuals filling prescriptions for two different P2Y12
antagonists within this interval were classified according
to the last prescription filled. Individuals failing to fill a
prescription for either a P2Y12 antagonist or ASA within
30 days after index MI were classified as not using DAPT.
Persistence with treatment was analysed during a
period of 365 days following the index MI using the
‘proportion of patients covered’ (PPC) method.18 In
brief, all participants were followed starting 30 days after
discharge from the index event. Over time, we estimated
the proportion of all participants still alive and not
migrated and using the same P2Y12 antagonist as at dis-
charge. A participant was considered a current user of a
given P2Y12 antagonist from the day of filling a prescrip-
tion for that drug and for a number of days correspond-
ing to either the number of tablets for clopidogrel and
prasugrel (used once daily) or half the number of
tablets for ticagrelor (used twice daily). Finally, a 30-day
grace period was added to the estimated duration to
account for minor non-compliance and irregular pre-
scription refills. A sensitivity analysis with a grace period
of 60 days was also performed. An individual could be
regarded as dropped out of treatment at one point in
time and later be reclassified as a current user on filling
a new prescription. In the Cox regression analysis for
having a treatment break larger than the 30-day grace
period, the type of DAPT treatment, age and gender,
type of treating hospital department and selected
comorbidities were chosen as covariates.
Frequency of switch between different DAPT regimens
To estimate switch patterns, we estimated the proportion
of all participants who within the first year following dis-
charge filled a P2Y12 antagonist other than the one they
first used following discharge. The observation period
for this analysis started 30 days after discharge with the
index admission of MI.
Statistical programme
All calculations were performed using STATA Release
V.13.0 (StataCorp, College Station, Texas, USA).
RESULTS
Overall, 97% (28 449 patients) of all patients admitted
to the hospital with a first-time MI during 2009–2012
were alive 30 days after discharge and included in this
study. The baseline characteristics for the years 2009 and
2012 are shown in tables 1 and 2. Baseline characteristics
for the total material as well as for the years 2010
and 2011 are contained in online supplementary tables
S1–S3, respectively.
Patient characteristics 2009
Of the patients with first-time MI (median age 69 years
(IQR 59–79 years); 36% women), 73% underwent angi-
ography and 53% PCI, and a majority of patients (67%)
were discharged with DAPT (table 1 and figure 1). A
larger proportion of patients with PCI were discharged
with DAPT (87%) compared with the patients without
PCI (51%). The PCI patients were younger and more
frequently men than the non-PCI patients. A majority of
these patients received ASA, β-blockers, ACE inhibitors
and statins at discharge, which is in line with guideline
recommendations. Among the non-PCI patients, a con-
siderably larger proportion underwent CABG, had a
diagnosis of atrial fibrillation and/or had a history of
major bleedings compared with the PCI patients.
Notably, a larger proportion of non-PCI patients were
discharged without β-blockers, ACE inhibitors and
statins.
Patient characteristics 2012
The median age of patients with first-time MI was
69 years (IQR 58–78 years), and 36% were women
(table 2). Overall, 79% underwent angiography and
55% PCI, and the majority (73%) were discharged with
DAPT (table 2 and figure 1). Still, a large proportion
(49%) of the non-PCI patients were discharged without
DAPT and other guideline recommended drug therap-
ies compared with the PCI patients. In general, marked
differences in patient characteristic were observed to be
dependent on the choice of P2Y12 antagonist used in
the DAPT regimens. Patients treated with prasugrel were
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Table 1 Baseline demographic and clinical characteristics for the 2009 first-time MI population
Patients with PCI (N=3576, 50%) Patients without PCI (N=3528, 50%)
All patients
n=3576
Clopidogrel
n=3087
Ticagrelor
n=0
Prasugrel
n=13
No DAPT
n=476
All patients
n=3528
Clopidogrel
n=1712
Ticagrelor
n=0
Prasugrel
n=1
No DAPT
n=1815
Age (median (IQR)) 64 (55–73) 64 (55–73) – 57 (50–64) 68 (59–75) 74 (64–83) 74 (64–83) – 49 (49–49) 74 (63–84)
Males 2643 (73.9%) 2289 (74.1%) 0 (%) 8 (61.5%) 346 (72.7%) 1951 (55.3%) 956 (55.8%) 0 (%) 0 (0.0%) 995 (54.8%)
Type of hospital (at index MI event)
Local hospital 946 (26.5%) 805 (26.1%) 0 (%) 5 (38.5%) 136 (28.6%) 1440 (40.8%) 659 (38.5%) 0 (%) <5 780 (43.0%)
Main regional hospital 1149 (32.1%) 1005 (32.6%) 0 (%) 5 (38.5%) 139 (29.2%) 1150 (32.6%) 616 (36.0%) 0 (%) 0 (0.0%) 534 (29.4%)
Tertiary cardiac hospital 1481 (41.4%) 1277 (41.4%) 0 (%) <5 201 (42.2%) 938 (26.6%) 437 (25.5%) 0 (%) 0 (0.0%) 501 (27.6%)
Procedures (at index event)
CABG 80 (2.2%) 47 (1.5%) 0 (%) 0 (0.0%) 33 (6.9%) 412 (11.7%) 197 (11.5%) 0 (%) 0 (0.0%) 215 (11.8%)
Angiography 3535 (98.9%) 3055 (99.0%) 0 (%) 13 (100.0%) 467 (98.1%) 1761 (49.9%) 932 (54.4%) 0 (%) <5 828 (45.6%)
Previous diagnoses
Heart failure 100 (2.8%) 71 (2.3%) 0 (%) 0 (0.0%) 29 (6.1%) 343 (9.7%) 148 (8.6%) 0 (%) 0 (0.0%) 195 (10.7%)
Ischaemic heart disease 256 (7.2%) 181 (5.9%) 0 (%) <5 74 (15.5%) 488 (13.8%) 199 (11.6%) 0 (%) 0 (0.0%) 289 (15.9%)
Unstable angina 55 (1.5%) 43 (1.4%) 0 (%) 0 (0.0%) 12 (2.5%) 107 (3.0%) 50 (2.9%) 0 (%) 0 (0.0%) 57 (3.1%)
Peripheral arterial disease 94 (2.6%) 67 (2.2%) 0 (%) 0 (0.0%) 27 (5.7%) 246 (7.0%) 118 (6.9%) 0 (%) 0 (0.0%) 128 (7.1%)
Stroke total 132 (3.7%) 98 (3.2%) 0 (%) <5 33 (6.9%) 338 (9.6%) 160 (9.3%) 0 (%) 0 (0.0%) 178 (9.8%)
Non-ischaemic stroke <5 <5 0 (%) 0 (0.0%) <5 19 (0.5%) 7 (0.4%) 0 (%) 0 (0.0%) 12 (0.7%)
Ischaemic stroke 130 (3.6%) 96 (3.1%) 0 (%) <5 33 (6.9%) 328 (9.3%) 155 (9.1%) 0 (%) 0 (0.0%) 173 (9.5%)
Atrial fibrillation 125 (3.5%) 93 (3.0%) 0 (%) 0 (0.0%) 32 (6.7%) 375 (10.6%) 132 (7.7%) 0 (%) 0 (0.0%) 243 (13.4%)
Chronic renal dysfunction 16 (0.4%) 11 (0.4%) 0 (%) 0 (0.0%) 5 (1.1%) 43 (1.2%) 18 (1.1%) 0 (%) 0 (0.0%) 25 (1.4%)
Diabetes mellitus 396 (11.1%) 327 (10.6%) 0 (%) <5 68 (14.3%) 625 (17.7%) 304 (17.8%) 0 (%) 0 (0.0%) 321 (17.7%)
Major bleeding 93 (2.6%) 75 (2.4%) 0 (%) 0 (0.0%) 18 (3.8%) 189 (5.4%) 67 (3.9%) 0 (%) 0 (0.0%) 122 (6.7%)
Liver disease <5 <5 0 (%) 0 (0.0%) 0 (0.0%) 5 (0.1%) <5 0 (%) 0 (0.0%) <5
Coagulation disorders 9 (0.3%) 8 (0.3%) 0 (%) 0 (0.0%) <5 21 (0.6%) <5 0 (%) 0 (0.0%) 17 (0.9%)
Cancer 193 (5.4%) 158 (5.1%) 0 (%) <5 34 (7.1%) 333 (9.4%) 146 (8.5%) 0 (%) 0 (0.0%) 187 (10.3%)
Drug use at discharge
Total number of drugs (median (IQR)) 3 (1–6) 3 (1–6) – 4 (0–8) 4 (2–8) 6 (3–10) 6 (3–10) – 13 (13–13) 7 (3–11)
ACE inhbitors and ARB 1948 (54.5%) 1678 (54.4%) 0 (%) 7 (53.8%) 263 (55.3%) 1984 (56.2%) 992 (57.9%) 0 (%) 0 (0.0%) 992 (54.7%)
Acetyl salicylic acid 3379 (94.5%) 3087 (100.0%) 0 (%) 13 (100.0%) 279 (58.6%) 2962 (84.0%) 1712 (100.0%) 0 (%) <5 1249 (68.8%)
β-blocker 3170 (88.6%) 2760 (89.4%) 0 (%) 12 (92.3%) 398 (83.6%) 2537 (71.9%) 1389 (81.1%) 0 (%) 0 (0.0%) 1148 (63.3%)
Calcium-channel blocker 749 (20.9%) 621 (20.1%) 0 (%) <5 127 (26.7%) 1027 (29.1%) 474 (27.7%) 0 (%) <5 552 (30.4%)
Oral antidiabetics and insulin 369 (10.3%) 308 (10.0%) 0 (%) <5 60 (12.6%) 562 (15.9%) 277 (16.2%) 0 (%) 0 (0.0%) 285 (15.7%)
Proton pump inhibitors 916 (25.6%) 772 (25.0%) 0 (%) <5 140 (29.4%) 1302 (36.9%) 579 (33.8%) 0 (%) <5 722 (39.8%)
Statins 3379 (94.5%) 2954 (95.7%) 0 (%) 12 (92.3%) 413 (86.8%) 2523 (71.5%) 1427 (83.4%) 0 (%) <5 1095 (60.3%)
Anticoagulant 224 (6.3%) 162 (5.2%) 0 (%) <5 61 (12.8%) 415 (11.8%) 113 (6.6%) 0 (%) 0 (0.0%) 302 (16.6%)
NSAIDs 613 (17.1%) 531 (17.2%) 0 (%) 5 (38.5%) 77 (16.2%) 606 (17.2%) 280 (16.4%) 0 (%) 0 (0.0%) 326 (18.0%)
Time until P2Y12 antagonist prescription claimed
Prior to MI 122 (3.4%) 103 (3.3%) 0 (%) <5 18 (3.8%) 167 (4.7%) 125 (7.3%) 0 (%) 0 (0.0%) 42 (2.3%)
1–7 days 3033 (84.8%) 2825 (91.5%) 0 (%) 11 (84.6%) 197 (41.4%) 1600 (45.4%) 1438 (84.0%) 0 (%) <5 161 (8.9%)
8–14 days 52 (1.5%) 48 (1.6%) 0 (%) 0 (0.0%) <5 69 (2.0%) 65 (3.8%) 0 (%) 0 (0.0%) <5
15–30 days 120 (3.4%) 111 (3.6%) 0 (%) <5 8 (1.7%) 91 (2.6%) 84 (4.9%) 0 (%) 0 (0.0%) 7 (0.4%)
No prescription 249 (7.0%) 0 (0.0%) 0 (%) 0 (0.0%) 249 (52.3%) 1601 (45.4%) 0 (0.0%) 0 (%) 0 (0.0%) 1601 (88.2%)
Numbers in parentheses are percentages of total number of patients in the group; local hospital, hospital without catheterisation laboratory; main regional hospital, hospital with catheterisation
laboratory; tertiary cardiac hospital, university hospital with catheterisation laboratory.
ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; MI, myocardial infarction; NSAIDs, non-steroidal anti-inflammatory drugs; PCI,
percutaneous coronary intervention.
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Table 2 Baseline demographic and clinical characteristics for the 2012 first-time MI population
Patients with PCI (n=3852, 55%) Non-PCI patients (n=3164, 45%)
All patients
n=3852
Clopidogrel
n=724
Ticagrelor
n=2238
Prasugrel
n=531
No DAPT
n=359
All patients
n=3164
Clopidogrel
n=679
Ticagrelor
n=921
Prasugrel
n=26
No DAPT
n=1538
Age (median (IQR)) 65 (55–74) 68 (58–79) 65 (55–74) 58 (51–66) 69 (59–77) 74 (63–83) 77 (67–86) 71 (61–80) 52.5 (48–67) 75 (64–84)
Males 2800 (72.7) 490 (67.7) 1615 (72.2) 440 (82.9) 255 (71.0) 1684 (53.2) 337 (49.6) 500 (54.3) 18 (69.2) 829 (53.9)
Type of hospital (at index MI event)
Local hospital 1037 (26.9) 291 (40.2) 552 (24.7) 68 (12.8) 126 (35.1) 1285 (40.6) 277 (40.8) 318 (34.5) <5 686 (44.6)
Main regional hospital 1579 (41.0) 202 (27.9) 1021 (45.6) 234 (44.1) 122 (34.0) 1144 (36.2) 247 (36.4) 417 (45.3) 8 (30.8) 472 (30.7)
Tertiary cardiac hospital 1236 (32.1) 231 (31.9) 665 (29.7) 229 (43.1) 111 (30.9) 735 (23.2) 155 (22.8) 186 (20.2) 14 (53.8) 380 (24.7)
Procedures (at index MI event)
CABG 93 (2.4) 40 (5.5) 20 (0.9) <5 30 (8.4) 453 (14.3) 77 (11.3) 130 (14.1) <5 245 (15.9)
Angiography 3790 (98.4) 704 (97.2) 2213 (98.9) 525 (98.9) 348 (96.9) 1740 (55.0) 340 (50.1) 649 (70.5) 16 (61.5) 735 (47.8)
Previous diagnoses
Heart failure 83 (2.2) 23 (3.2) 34 (1.5) 7 (1.3) 19 (5.3) 234 (7.4) 67 (9.9) 41 (4.5) 0 (0.0) 126 (8.2)
Ischaemic heart disease 210 (5.5) 59 (8.1) 90 (4.0) 16 (3.0) 45 (12.5) 413 (13.1) 108 (15.9) 101 (11.0) <5 200 (13.0)
Unstable angina pectoris 46 (1.2) 14 (1.9) 21 (0.9) <5 9 (2.5) 77 (2.4) 18 (2.7) 14 (1.5) <5 43 (2.8)
Peripheral arterial disease 110 (2.9) 36 (5.0) 44 (2.0) 6 (1.1) 24 (6.7) 224 (7.1) 61 (9.0) 55 (6.0) 0 (0.0) 108 (7.0)
Stroke total 126 (3.3) 36 (5.0) 62 (2.8) <5 25 (7.0) 257 (8.1) 86 (12.7) 40 (4.3) 0 (0.0) 131 (8.5)
Non-ischaemic stroke 12 (0.3) <5 6 (0.3) 0 (0.0) <5 22 (0.7) 5 (0.7) <5 0 (0.0) 14 (0.9)
Ischaemic stroke 117 (3.0) 33 (4.6) 58 (2.6) <5 23 (6.4) 243 (7.7) 83 (12.2) 38 (4.1) 0 (0.0) 122 (7.9)
Atrial fibrillation 150 (3.9) 44 (6.1) 56 (2.5) 5 (0.9) 45 (12.5) 335 (10.6) 63 (9.3) 49 (5.3) 0 (0.0) 223 (14.5)
Chronic renal dysfunction 30 (0.8) 8 (1.1) 11 (0.5) <5 10 (2.8) 41 (1.3) 11 (1.6) <5 <5 24 (1.6)
Diabetes mellitus 512 (13.3) 114 (15.7) 279 (12.5) 53 (10.0) 66 (18.4) 585 (18.5) 157 (23.1) 140 (15.2) <5 284 (18.5)
Major bleeding 88 (2.3) 26 (3.6) 41 (1.8) 7 (1.3) 14 (3.9) 155 (4.9) 33 (4.9) 33 (3.6) 0 (0.0) 89 (5.8)
Liver disease 9 (0.2) <5 <5 <5 <5 7 (0.2) <5 <5 0 (0.0) <5
Coagulation disorders 15 (0.4) 5 (0.7) <5 0 (0.0) 6 (1.7) 17 (0.5) <5 <5 0 (0.0) 14 (0.9)
Cancer 278 (7.2) 66 (9.1) 145 (6.5%) 25 (4.7) 42 (11.7) 339 (10.7) 63 (9.3) 86 (9.3) 0 (0.0) 190 (12.4)
Drug use at discharge
Total number of drugs (median (IQR)) 3 (1–6) 4 (1–8) 3 (1–6) 2 (0–4) 5 (2–8) 6 (3–10) 7 (4–11) 5 (2–9) 4.5 (1–6) 7 (3–11)
ACE inhibitors and ARB 2076 (53.9) 450 (62.2) 1145 (51.2) 268 (50.5) 213 (59.3) 1748 (55.2) 417 (61.4) 495 (53.7) 15 (57.7) 821 (53.4)
Acetyl salicylic acid 3666 (95.2) 724 (100.0) 2238 (100.0) 531 (100.0) 173 (48.2) 2568 (81.2) 679 (100.0) 921 (100.0) 26 (100.0) 942 (61.2)
β-blocker 3364 (87.3) 621 (85.8) 1959 (87.5) 503 (94.7) 281 (78.3) 2226 (70.4) 517 (76.1) 754 (81.9) 20 (76.9) 935 (60.8)
Calcium-channel blocker 877 (22.8) 218 (30.1) 463 (20.7) 79 (14.9) 117 (32.6) 1073 (33.9) 247 (36.4) 305 (33.1) 12 (46.2) 509 (33.1)
Oral antidiabetics and insulin 473 (12.3) 98 (13.5) 265 (11.8) 49 (9.2) 61 (17.0) 532 (16.8) 147 (21.6) 133 (14.4) <5 248 (16.1)
Proton pump inhibitors 1195 (31.0) 275 (38.0) 680 (30.4) 108 (20.3) 132 (36.8) 1280 (40.5) 322 (47.4) 323 (35.1) 9 (34.6) 626 (40.7)
Statins 3661 (95.0) 672 (92.8) 2165 (96.7) 524 (98.7) 300 (83.6) 2219 (70.1) 529 (77.9) 802 (87.1) 22 (84.6) 866 (56.3)
Anticoagulant 266 (6.9) 76 (10.5) 94 (4.2) 14 (2.6) 82 (22.8) 445 (14.1) 65 (9.6) 63 (6.8) 0 (0.0) 317 (20.6)
NSAIDs 624 (16.2) 118 (16.3) 367 (16.4) 79 (14.9) 60 (16.7) 539 (17.0) 104 (15.3) 159 (17.3) 8 (30.8) 268 (17.4)
Time until P2Y12 antagonist prescription claimed
Prior to MI 165 (4.3) 48 (6.6) 80 (3.6) 16 (3.0) 21 (5.8) 228 (7.2) 121 (17.8) 45 (4.9) <5 61 (4.0)
1–7 days 3472 (90.1) 656 (90.6) 2123 (94.9) 508 (95.7) 185 (51.5) 1543 (48.8) 521 (76.7) 833 (90.4) 24 (92.3) 165 (10.7)
8–14 days 32 (0.8) 8 (1.1) 11 (0.5) 7 (1.3) 6 (1.7) 46 (1.5) 21 (3.1) 21 (2.3) 0 (0.0) <5
15–30 days 44 (1.1) 12 (1.7) 24 (1.1) 0 (0.0) 8 (2.2) 49 (1.5) 16 (2.4) 22 (2.4) <5 10 (0.7)
No prescription 139 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 139 (38.7) 1298 (41.0) 0 (0.0) 0 (0.0) 0 (0.0) 1298 (84.4)
Tertiary cardiac hospital, university hospital with catheterisation laboratory.
Local hospital, hospital without catheterisation laboratory; main regional hospital, hospital with catheterisation laboratory.
Numbers in parentheses are percentages of total number of patients in the group.ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; MI,
myocardial infarction; NSAIDs, non-steroidal anti-inflammatory drugs; PCI, percutaneous coronary intervention.
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11 years younger (median), more commonly men and
the majority underwent PCI (84%) compared with the
total MI patient population. Most of the prasugrel-
treated patients were either managed at a main regional
hospital or at a university hospital with a catheterisation
laboratory.
The proportion of patients prescribed DAPT with tica-
grelor increased quickly after its introduction in 2011.
By the end of 2012, ticagrelor was the most common
P2Y12 antagonist in patients with and without PCI
(figure 1). More patients in the ticagrelor group under-
went PCI (71%) compared with clopidogrel-treated
patients (52%). Ticagrelor-treated patients were 7 years
younger and more commonly men. Patients treated with
clopidogrel had in general a more severe disease
burden at baseline, with additional diagnoses of heart
failure, stroke or atrial fibrillation compared with the
other DAPT-treated patients (table 2).
In 2012, the proportion of patients discharged with
DAPT was 6% higher compared with that in 2009. The
non-DAPT-treated patients were older (+9 years, median
age difference) and more commonly women (+20% dif-
ference) compared with the DAPT-treated patients.
Among non-DAPT-treated patients, invasive treatment
within 30 days from admission was received by relatively
few patients; 57% underwent angiography and 19% PCI.
A larger proportion of non-DAPT-treated patients under-
went CABG, were diagnosed with atrial fibrillation and
were treated with warfarin or new oral anticoagulants
(NOAC) compared with the DAPT-treated patients.
More patients had a prior diagnosis of heart failure,
cancer and/or a history of major bleeds or coagulation
disorders.
A smaller proportion of the non-DAPT-treated patients
received ACE inhibitors/angiotensin receptor blockers
(ARBs), β-blockers and statins at discharge compared
with DAPT-treated patients. Of these, 49% received ASA
as monotherapy, and 13% and 10% of
non-DAPT-treated patients were treated with clopidogrel
or ticagrelor, respectively, as monotherapies.
Medical history-related predictors of DAPT persistence
Overall, persistence was very high among patients
initiated on DAPT (figure 2).
Within the first year post-MI in 2012, 6% of the
prasugrel-treated patients were switched to another
P2Y12 antagonist; 11% from the ticagrelor group and 3%
from the clopidogrel group (table 3).
Patients undergoing PCI had a longer DAPT duration
overall compared with patients not undergoing PCI, and
age>75 years and diagnosis of atrial fibrillation, diabetes
and peripheral arterial disease were associated with a
higher risk of treatment breaks (table 4). Furthermore,
there was a trend towards increased risk for treatment
breaks for PCI patients with heart failure and stroke. For
patients not undergoing PCI, we did not observe any
association between any major baseline diseases and risk
for treatment breaks.
Among PCI patients, treatment with prasugrel or tica-
grelor compared with clopidogrel was associated with an
increased risk of a 30-day treatment break within
365 days after MI (table 4). However, this risk was not
present when extending the grace period to 60 days
(data not shown).
For non-PCI patients, ticagrelor compared with clopi-
dogrel treatment was associated with an increased risk of
having a 30-day treatment break. This finding was also
present when expanding the grace period to 60 days,
during which 11% of these patients were switched to clo-
pidogrel after a median of 107 days.
DISCUSSION
This nationwide observational study showed changes in
the treatment of patients with MI in Denmark from 2009
to 2012. In 2012, more patients are referred to coronary
angiography and PCI, and a larger proportion of patients
are discharged with DAPT compared to 2009. However,
Figure 1 Proportion of patients with first-time MI discharged
alive with or without PCI and prescribed different types of
DAPT or no DAPT 2009–2012. DAPT, dual antiplatelet
therapy; MI, myocardial infarction; PCI, percutaneous
coronary intervention.
6 Green A, et al. BMJ Open 2016;6:e010880. doi:10.1136/bmjopen-2015-010880
Open Access
non-PCI patients were, to a large extent, discharged
without DAPT, or received shorter duration of DAPT treat-
ment as compared with PCI patients. Among PCI patients,
age>75 years, atrial fibrillation, diabetes and peripheral
arterial disease were all associated with a higher risk of
treatment breaks, which might indicate a risk–treatment
mismatch, as these patients have a higher risk of recurrent
events and might benefit from longer DAPT duration.
During the observation period, the DAPT pattern shifted
from merely clopidogrel treatment to more selective treat-
ments with clopidogrel, prasugrel and ticagrelor for
patient populations with varying characteristics.
Interpretation with reference to other studies
The underlying medical treatment of patients with MI in
Denmark, with more patients undergoing angiography
and PCI over time, followed the same trend as seen both
in earlier observations in Denmark and studies from
other countries.19–21
To the best of our knowledge, national-level data
describing patient selection for different DAPT regimens
and persistence with treatment in unselected popula-
tions are scarce. Publications based on data from cardio-
vascular quality registers, actively recruiting or selecting
patients, report an overall DAPT usage for discharged
Figure 2 Persistence with different dual antiplatelet therapy in patients with first-time MI with or without PCI 2009–2012. MI,
myocardial infarction; PCI, percutaneous coronary intervention.
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patients with ACS in the range of ∼60–80% depending
on the observation period and the type of ACS event
included.21–25 A recent Swedish nationwide study on
patients with MI, which may be considered comparable
to the present nationwide data, reported a DAPT usage
of 69% for patients discharged with MI in 2000–2011.26
A previous similar Danish study, including all patients
with MI between 2000 and 2005, reported an increasing
use of DAPT during the observation period.7 However,
for non-PCI patients, there was a substantial underuse,
especially among women and patients admitted to local
hospitals. Although the observation period in this study
is more recent, many of these patients are still dis-
charged without DAPT, although there is a markedly
increased use of DAPT in these patient groups.
The observed overall adherence to DAPT (figure 2), with
more than 75% of patients completing more than
11 months of treatment, is noteworthy and comparable to
what has been observed in randomised controlled trials.27 28
Medical history-related predictors of DAPT persistence
The non-DAPT-treated patients are of special interest, as in
this study they form a considerable proportion of patients
discharged with first-time MI (27% in 2012), despite the
decline in the relative number of patients discharged
without DAPT during the observation period (figure 2). A
large proportion of these patients received oral antiplatelet
monotherapy with ASA or with prasugrel, ticagrelor or clo-
pidogrel. Furthermore, there was a marked difference
between patients who underwent PCI versus those who did
not; a larger proportion of non-PCI patients were dis-
charged without DAPT (in 2012: 9% vs 49%, respectively).
In addition, non-PCI patients had a shorter DAPT treat-
ment duration in general, were on average 10 years older
and with a large proportion having a risk profile with atrial
fibrillation and history of bleedings where a shorter DAPT
duration or no DAPT treatment may be appropriate.
However, many of these patients had a high cardiovascular
disease risk profile at baseline, suggesting a potential
benefit of a longer DAPT treatment duration and more
frequent use of β-blockers, ACE inhibitors and statins.
Thus, potentially, there exists a risk–treatment mis-
match with treatment being withheld from patients who
might receive similar or more benefit of longer DAPT.
Comparison of adherence to different DAPT alternatives
A direct comparison of adherence and treatment length
between the different DAPT alternatives after MI is
complex because the treatments in clinical practice are
prescribed to different patient populations. Even in com-
parable populations, it is difficult to standardise adher-
ence in a multivariable model as underlying factors (such
as tablet pack size and daily dosing patterns) may influ-
ence treatment length. Similarly, it is difficult to assess
how these underlying factors influence the risk of having
a calculated treatment break of 30 days.
Prasugrel is prescribed almost entirely for patients
with PCI, whereas clopidogrel and ticagrelor are
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prescribed irrespective of PCI status. In patients with
PCI, the adherence patterns did not differ between the
respective DAPTs, whereas non-PCI patients had a gen-
erally shorter treatment length and those prescribed
ticagrelor showed an increased risk of early treatment
break compared with patients prescribed clopidogrel;
some of these patients (11%) were switched to clopido-
grel. We did not have access to data that would provide
reasons for this shorter treatment length or treatment
switch, such as if this switch was carried out in a hospital
setting, by general practitioners, or in certain geograph-
ical locations. Moreover, a relatively large proportion
(18%) of patients not undergoing PCI were already on
clopidogrel before their MI event, indicating an under-
lying long-term use not associated with the MI which
may explain the longer observed treatment length in
this group. In addition, it seems that a larger proportion
of clopidogrel patients, both with and without PCI, are
treated for more than 12 months after MI.
Strength and limitations
Our data set is uniquely placed to examine DAPT adher-
ence because it includes nationwide data from all patients
hospitalised in Denmark for MI, allowing analyses on a
complete and unselected cohort of patients. This reduces
potential problems arising from selection bias due to
inclusion of selected hospitals, regions or healthcare
insurance systems. We believe our results may be general-
ised to societies with healthcare systems comparable to the
one in Denmark. However, this study design also comes
with certain limitations. A register-based analysis relies on
ICD-10 codes for morbidity data, and therefore the possi-
bility of coding errors cannot be ruled out. Therefore,
patients with unstable angina pectoris diagnosis were not
included and subcoding into STEMI and NSTEMI was not
performed. However, the diagnosis of MI in the Danish
National Patient Registry has previously been shown to
have both high sensitivity and high specificity.29 Further,
treatment guidelines for DAPT initiation and treatment
duration do not differ between STEMI and NSTEMI.5 6
Since our study is based on central registry data col-
lected primarily for administrative purposes, it is not pos-
sible to include clinical data on smoking pattern, weight,
blood pressure, laboratory data or socioeconomic status.
Furthermore, data on events (recurrent MI, elective PCI,
bleedings) during follow-up that might influence treat-
ment length were not included in the current analysis
because of the complexity of different patient baseline
risks for the DAPTs.
CONCLUSIONS
The results from this study show that the treatment of
patients with MI in Denmark has undergone major
changes during 2009–2012. More patients undergo
Table 4 Patients with MI discharged in 2012: Cox regression analysis: HR for having a break in P2Y12 antagonist treatment
>30 days with or without PCI
Patients with PCI Non-PCI patients
Number of
patients
Number of
patients with
breaks HR (95% CI)
Number of
patients
Number of
patients with
breaks HR (95% CI)
All patients 3373 1513 1399 972
Clopidogrel 697 317 Reference 579 411 Reference
Ticagrelor 2164 937 1.20 (1.03 to 1.39) 800 552 1.48 (1.27 to 1.72)
Prasugrel 512 259 1.48 (1.24 to 1.78) 20 9 0.86 (0.47 to 1.58)
Female 911 398 Reference 666 481 Reference
Male 2462 1115 1.00 (0.88 to 1.13) 733 491 0.91 (0.78 to 1.05)
<60 years 1216 503 1.01 (0.90 to 1.14) 277 168 1.18 (0.97 to 1.43)
60 to 75 years 1481 648 Reference 554 344 Reference
>75 years 676 362 1.15 (1.00 to 1.34) 568 460 1.02 (0.86 to 1.21)
Local hospital 878 403 Reference 498 357 Reference
Main regional hospital 1404 620 0.97 (0.85 to 1.11) 588 399 0.99 (0.84 to 1.18)
Tertiary cardiac hospital 1091 490 1.00 (0.86 to 1.15) 313 216 1.12 (0.92 to 1.38)
CABG 56 22 0.81 (0.49 to 1.34) 191 107 1.00 (0.80 to 1.25)
Heart failure 59 42 1.40 (0.94 to 2.08) 86 79 1.33 (0.98 to 1.81)
Stroke 97 56 1.34 (0.99 to 1.82) 101 77 1.11 (0.82 to 1.49)
Atrial fibrillation 92 68 1.88 (1.41 to 2.50) 94 81 1.27 (0.95 to 1.70)
Diabetes 411 229 1.23 (1.05 to 1.44) 258 196 0.96 (0.79 to 1.16)
Cancer 219 131 1.09 (0.88 to 1.34) 125 104 1.03 (0.80 to 1.33)
Major bleeding 67 39 1.07 (0.74 to 1.56) 53 36 1.20 (0.86 to 1.67)
Peripheral arterial
disease
85 61 1.63 (1.20 to 2.20) 93 74 0.99 (0.72 to 1.36)
Local hospital, hospital without catheterisation laboratory; main regional hospital, hospital with catheterisation laboratory; tertiary cardiac
hospital, university hospital with catheterisation laboratory.
CABG, coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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invasive procedures (coronary angiography and PCI), and
the DAPT pattern has shifted from merely clopidogrel to
different treatments for selected patient populations. The
majority of patients are discharged with DAPT and the
overall treatment length is according to guidelines and in
line with what has been observed in randomised con-
trolled clinical trials. Still, there is a proportion of patients
not undergoing PCI who are discharged without
guideline-recommended DAPT. If treated with DAPT, they
have a shorter treatment length. The present findings may
indicate the need for more careful attention with regard
to DAPT for patients with MI without PCI in Denmark.
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